Lanthanide-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid complex (Ln-DOTA)

Lanthanide-DOTA complexes are a class of macrocyclic coordination compounds consisting of a lanthanide ion (such as Gadolinium, Lutetium, or Yttrium) chelated by the ligand 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (PubChem CID 67635). These complexes are widely used in medical imaging and targeted radiotherapy due to their high thermodynamic stability and kinetic inertness, which prevents the release of toxic free metal ions into the body (Journal of Magnetic Resonance Imaging, 2012). In diagnostic applications, Gadolinium-DOTA (Gadoterate) serves as a contrast agent for magnetic resonance imaging (MRI) by enhancing the relaxation rates of water protons. In oncology, DOTA is often conjugated to targeting vectors like peptides to deliver radioactive lanthanides specifically to tumor cells for imaging or peptide receptor radionuclide therapy (PRRT) (FDA, 2018). While generally safe, clinical monitoring is required due to the risk of nephrogenic systemic fibrosis in patients with severe renal impairment and concerns regarding long-term lanthanide retention in tissues (EMA, 2017).

Other names

Lanthanide-DOTA complexesLn(III)-DOTAMacrocyclic lanthanide chelatesDOTA-metal complexesLanthanide-tetraazacyclododecane tetraacetic acid

Lanthanide-DOTA complexes function by sequestering lanthanide ions within a macrocyclic cage to ensure biological safety while utilizing the metal's physical properties. In MRI, paramagnetic ions like Gadolinium (Gd3+) shorten proton relaxation times to enhance image contrast (FDA, 2013). In nuclear medicine, DOTA is conjugated to targeting peptides (e.g., DOTATATE) to deliver beta-emitting (e.g., 177Lu) or alpha-emitting lanthanides for localized tumor destruction, or positron-emitting isotopes for PET imaging (Lutathera; FDA, 2018).